PDCD1 and neoplasm: While cellular and molecular immunophenotyping demonstrated a robust reprogramming of both innate and adaptive anti-tumor immunity in response to E7046 + E7777 combination therapy, it also induced expression of genes encoding immunosuppressive molecules such as ido1, arg1, PD-1, PD-L1, and Tim3.